HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2019)... , ... February 20, 2019 , ... ... announced plans today to expand the company’s footprint in Frederick, MD after a ... have used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their ...
(Date:2/22/2019)... ... , ... Clean label food is not just another passing trend in the ... is quite common to spot consumers running their index finger across the back of ... label scrutiny. , More than ever, meat and poultry producers are working diligently ...
(Date:2/22/2019)... ... February 21, 2019 , ... ... implanted SpineFrontier’s SacroFuse system in conjunction with NanoFUSE’s Orthobiologic ... case represents the first time that either SacroFuse or NanoFUSE have been used ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... ... This free webinar will review strategies for data management in modular and adaptive ... build times by up to 30 percent, reducing cost while increasing quality, achieving clinical site ... need to migrate data – reducing risk and impact on trial success, trial teams, and ...
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO ... Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical ... as the fifth institution in Oklahoma to receive this prestigious endorsement. The ...
(Date:3/14/2019)... ... March 13, 2019 , ... The International Society for ... taking place in Brussels, Belgium on 25–26 September 2019. This event is a ... innovative approaches. , “Biopharmaceuticals have become a main pillar in the pharmaceutical ...
(Date:3/11/2019)... ... March 11, 2019 , ... USDM Life Sciences and Generis ... with built in GxP compliance for the life sciences industry. USDM Cloud Assurance ... continuous compliance for Generis’ flagship product, CARA. , Presentation One:, ...
Breaking Biology Technology:
Cached News: